Idorsia Ltd
Research Idorsia Ltd (IDIA) on Bullrun: market cap CHF 1.46B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIDIA
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCHF
- Market capCHF 1.46B
- Financial periodQ1 2026
- RevenueCHF 57.39M
- Net income-CHF 45.70M
- Free cash flow-CHF 28.25M
- Gross margin86.0%
Valuation Snapshot
latest market cap is CHF 1.46B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | CHF 1.46B | n/a | n/a | n/a |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Idorsia Ltd's market cap?
Idorsia Ltd's market capitalization is CHF 1.46B.
What does Idorsia Ltd do?
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia.